Abstract
Background and Objective: There has been little advancement in the management of resectable non-small cell lung cancer (NSCLC) regarding neoadjuvant and adjuvant setting for almost two decades. Five-year survival rates for radically resected early stage NSCLC remain disappointing. The objective of this narrative review is to assess the current aspects and challenges of neoadjuvant targeted therapy in oncogene-driven NSCLC patients.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
